Abstract:Members of the steroid receptor coactivator (SRC) family are overexpressed in numerous types of cancers. In particular, steroid receptor coactivator 3 (SRC-3) has been recognized as a critical coactivator associated with tumor initiation, progression, recurrence, metastasis, and chemoresistance where it interacts with multiple nuclear receptors and other transcription factors to enhance their transcriptional activities and facilitate cross-talk between pathways that stimulate cancer progression. Because of its central role as an integrator of growth signaling pathways, development of small molecule inhibitors (SMIs) against SRCs have the potential to simultaneously disrupt multiple signal transduction networks and transcription factors involved in tumor progression. Here, high-throughput screening was performed to identify compounds able to inhibit the intrinsic transcriptional activities of the three members of the SRC family. Verrucarin A was identified as a SMI that can selectively promote the degradation of the SRC-3 protein, while affecting SRC-1 and SRC-2 to a lesser extent and having no impact on CARM-1 and p300 protein levels. Verrucarin A was cytotoxic toward multiple types of cancer cells at low nanomolar concentrations, but not toward normal liver cells. Moreover, verrucarin A was able to inhibit expression of the SRC-3 target genes MMP2 and MMP13 and attenuated cancer cell migration. We found that verrucarin A effectively sensitized cancer cells to treatment with other anti-cancer drugs. Binding studies revealed that verrucarin A does not bind directly to SRC-3, suggesting that it inhibits SRC-3 through its interaction with an upstream effector. In conclusion, unlike other SRC SMIs characterized by our laboratory that directly bind to SRCs, verrucarin A is a potent and selective SMI that blocks SRC-3 function through an indirect mechanism.

SRC-3 Has a Role in Cancer Other Than As a Nuclear Receptor Coactivator

SRC-3, a Steroid Receptor Coactivator: Implication in Cancer

Identification of SRC3/AIB1 as a Preferred Coactivator for Hormone-activated Androgen Receptor

Differential Gene Regulation by the SRC Family of Coactivators.

Critical Roles of SRC-3 in the Development and Progression of Breast Cancer, Rendering It a Prospective Clinical Target

The Steroid Receptor Coactivator SRC-3 (P/cip/rac3/aib1/actr/tram-1) is Required for Normal Growth, Puberty, Female Reproductive Function, and Mammary Gland Development.

Stimulation of Steroid Receptor Coactivator-3 (SRC-3) Gene Overexpression by a Positive Regulatory Loop of E2F1 and SRC-3.

Review of the in vivo functions of the p160 steroid receptor coactivator family.

The multifaceted therapeutic value of targeting steroid receptor coactivator-1 in tumorigenesis

Steroid receptor coactivator 3 ( SRC-3 / AIB1 ) is enriched and functional in mouse and human Tregs

Data from the Steroid Receptor Coactivator-3 is Required for the Development of Castration-Resistant Prostate Cancer

The role of SRC-1 in murine prostate cancinogenesis is nonessential due to a possible compensation of SRC-3/AIB1 overexpression

The SRC-3/AIB1 Coactivator is Degraded in a Ubiquitin- and ATP-Independent Manner by the REGγ Proteasome

Src-3 Ubiquination, Mediated by Cullin3, Potentiates Gambogic Acid-Induced Apoptosis in Non-Hodgkin'S Lymphoma

SRC-3/AIB1 Protein and Gene Amplification Levels in Human Esophageal Squamous Cell Carcinomas.

Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor

SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.

Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer

Steroid receptor coactivator-3 inhibition generates breast cancer antitumor immune microenvironment

A SNP in Steroid Receptor Coactivator-1 Disrupts a GSK3β Phosphorylation Site and is Associated with Altered Tamoxifen Response in Bone.

Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/β-Catenin Signaling